SLT lasers do not infringe Trimedyne's '737 patent, district court rules.
This article was originally published in The Gray Sheet
Executive SummarySLT CONTACT LASER PRODUCTS DO NOT INFRINGE TRIMEDYNE PATENT covering laser probes for thermal tissue ablation, the U.S. District Court for the Central District of California ruled Nov. 8. The court granted Surgical Laser Technologies' motion for summary judgment that its contact laser products do not infringe Trimedyne's patent No. 4,646,737.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.